Mark Bathe

Mark Bathe is a Professor of Biological Engineering at the Massachusetts Institute of Technology (MIT), where he leads the Bathe BioNano Lab within the Department of Biological Engineering in the School of Engineering. He is also a member of the Harvard Medical School (HMS) Initiative for RNA Medicine and an associate member of the Broad Institute of MIT & Harvard, reflecting his interdisciplinary impact across engineering, medicine, and genomics.

Professor Bathe earned his Bachelor’s, Master’s, and Doctoral degrees from MIT across Mechanical, Chemical, and Biological Engineering departments, followed by postdoctoral research at the University of Munich. He returned to MIT in 2009 to establish his research program focused on nucleic acid nanotechnology.

His research centers on nucleic acid nanotechnology to engineer programmable DNA and RNA materials at the nanometer-scale (10,000x smaller than a human hair). Key interests include biological imaging, biomechanics, biomolecular engineering, biophysics, and computational modeling for applications in therapeutic delivery, vaccines, molecular data storage, and quantum computing. His lab uniquely combines principles of structural DNA nanotechnology with functional biomolecular design to create custom nanoscale architectures with precise control over 2D/3D structure and chemical composition.

Analysis of his 15 most recent publications (2024-2025) reveals three dominant trends: (1) AI-driven characterization of DNA nanostructures using convolutional neural networks, (2) development of DNA origami platforms for vaccine design and immune stimulation, and (3) engineering nucleic acid systems for molecular data storage and quantum sensing. These works consistently bridge computational design, nanofabrication, and biological validation across neuroscience, virology, and photonics domains.

Professor Bathe runs an active interdisciplinary research group mentoring students in the Bathe BioNano Lab. His team develops both computational design frameworks (e.g., ATHENA for DNA origami) and experimental protocols for high-scale fabrication of nucleic acid materials. Current projects include targeted delivery of CRISPR therapeutics, phenotypic profiling of neuronal circuits in psychiatric disease, and quantum computing applications using DNA-scaffolded chromophores.

The lab operates within MIT’s state-of-the-art facilities, collaborating with the Broad Institute for genomic applications and HMS for translational medicine. Ongoing work focuses on overcoming clinical translation barriers for nucleic acid nanotechnology through scalable manufacturing techniques and rigorous in vivo validation, with commercial applications in vaccines, data storage, and quantum information processing.